These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Paquette RL; Meshkinpour A; Rosen PJ Medicine (Baltimore); 1994 May; 73(3):145-52. PubMed ID: 8190037 [TBL] [Abstract][Full Text] [Related]
9. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report. Petrini M; Cecconi N; Ambrogi F; Grassi B Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118 [No Abstract] [Full Text] [Related]
10. High dose i.v. MP for idiopathic myelofibrosis: a further case. Ozsoylu S Eur J Haematol; 1988 Mar; 40(3):282. PubMed ID: 3356246 [No Abstract] [Full Text] [Related]
11. Pyoderma gangrenosum associated with idiopathic myelofibrosis. Case history. Sgarabotto D; Vianello F; Valeri P; Tison T; Caenazzo A; Pietrogrande F; Poletti A; Girolami A Haematologia (Budap); 1993; 25(4):249-52. PubMed ID: 8157206 [TBL] [Abstract][Full Text] [Related]
12. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Pullarkat V; Bass RD; Gong JZ; Feinstein DI; Brynes RK Am J Hematol; 2003 Jan; 72(1):8-12. PubMed ID: 12508261 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203 [TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis: response to busulfan after hydroxyurea failure. Naqvi T; Baumann MA Int J Clin Pract; 2002 May; 56(4):312-3. PubMed ID: 12074218 [TBL] [Abstract][Full Text] [Related]
15. Idiopathic myelofibrosis associated with dermatomyositis. Muslimani A; Ahluwalia MS; Palaparty P; Daw HA Am J Hematol; 2006 Jul; 81(7):559-60. PubMed ID: 16755562 [No Abstract] [Full Text] [Related]
16. Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study. Galimberti S; Canestaro M; Ciancia E; Fazzi R; Marasca R; Petrini M Leuk Res; 2008 Aug; 32(8):1324-5. PubMed ID: 18192008 [No Abstract] [Full Text] [Related]
17. Treatment with valproic acid for myelofibrosis with myeloid metaplasia. Inoue Y; Suzuki T; Takimoto M; Irei M; Yoshioka S; Shibuya Y; Kato M; Koike M; Takahashi M Ann Hematol; 2005 Nov; 84(12):833-4. PubMed ID: 16132902 [No Abstract] [Full Text] [Related]
18. [Myelobromel in the treatment of patients with idiopathic myelofibrosis during erythremic phase]. Komiva NF Probl Gematol Pereliv Krovi; 1970 Jan; 15(1):50-3. PubMed ID: 5420384 [No Abstract] [Full Text] [Related]
19. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis]. Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028 [TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Huang J; Tefferi A Eur J Haematol; 2009 Aug; 83(2):154-5. PubMed ID: 19366369 [No Abstract] [Full Text] [Related] [Next] [New Search]